UK Markets closed

Biotest Aktiengesellschaft (0N70.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
43.52+0.12 (+0.28%)
At close: 5:43PM BST
Full screen
Previous close43.40
Open43.48
Bid0.00 x 0
Ask0.00 x 0
Day's range43.48 - 43.52
52-week range43.48 - 43.52
Volume9,497
Avg. volumeN/A
Market cap1.797B
Beta (5Y monthly)0.52
PE ratio (TTM)N/A
EPS (TTM)-0.89
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Biotest AG: Biotest identifies a benefit with trimodulin in a relevant subgroup of hospitalised COVID-19 patients

    DGAP-News: Biotest AG / Key word(s): Research Update11.10.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest identifies a benefit with trimodulin in a relevant subgroup of hospitalised COVID-19 patients- Complete data set from the phase II ESsCOVID trial analysed- Post hoc subgroup analyses revealed a medical relevant benefit in hospitalised COVID-19 patients with early systemic inflammation- Biotest considers further clinical development of t

  • EQS Group

    Biotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG

    Biotest AG / Key word(s): OfferBiotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG17-Sep-2021 / 12:52 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Takeover Offer: Grifols S.A.

  • Reuters

    Spain's Grifols to buy rival Biotest for up to $1.9 billion

    MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.